Secondary prevention of atherothrombotic complications; in adult patients after a recent myocardial infarction (from a few days to 35 days), a recent ischemic stroke (from 7 days to 6 months), or with diagnosed occlusive peripheral arterial disease, clopidogrel administration reduced the frequency of the combined endpoint, which included repeated ischemic stroke (with or without lethal outcome), repeated myocardial infarction (with or without lethal outcome) and other cardiovascular death; in adult patients with acute coronary syndrome - acute coronary syndrome without ST-segment elevation (unstable angina / myocardial infarction without Q wave), including patients who should receive medical treatment and patients who are indicated for percutaneous coronary intervention (with or without stenting) or coronary artery bypass grafting (CABG), acute myocardial infarction with ST segment elevation. Prevention of atherothrombotic and thromboembolic complications in adult patients with atrial fibrillation (atrial fibrillation). Indications: Unstable angina pectoris, Acute myocardial infarction, Pulmonary embolism, Atrial fibrillation and flutter, Brain infarction, Other peripheral vascular diseases, Embolism and thrombosis of arteries, Embolism and thrombosis of other veins.